Northern Biologics, a developer of first-in-class immuno-oncology products, began clinical testing of its lead antibody MSC-1 in June 2018. The first trial site was Memorial Sloan Kettering Cancer Center in New York, with plans to expand to leading sites in Canada and Europe. Northern Biologics merged with Metrix Partners client Mosaic Biomedicals in 2016.

About MSC-1 and LIF
MSC-1 is a humanised antibody against leukaemia inhibitory factor (LIF), a soluble cytokine. LIF plays several roles in cancer, so blocking it opens two possible therapeutic effects: reversing immune suppression around the tumour, and blocking tumour growth by inhibiting cancer-initiating cells. The announcement was published on Business Wire.
MSC-1 was developed by Mosaic Biomedicals in Barcelona, building on research into LIF in tumours. It came into Northern Biologics through the merger of the two companies, backed by Versant Ventures and Celgene.
Why entering the clinic matters
Moving from preclinical studies to the first patient is one of the main value points for a biotech company. It shows that the molecule can be manufactured to clinical standards, that regulators have accepted the safety data, and that leading cancer centres want to run the study. It also opens the possibility of partnering discussions with large pharmaceutical companies.
What happened next
Northern Biologics presented Phase 1 dose-escalation results at the AACR annual meeting in 2020, showing MSC-1 was safe and well tolerated in patients with advanced solid tumours. In May 2020, Boehringer Ingelheim acquired its preclinical pipeline, and in November 2020 an AstraZeneca subsidiary acquired MSC-1.
Five lessons for oncology biotech companies
- Top clinical sites add credibility. Running trials at leading cancer centres attracts investigators and partners.
- Biology drives interest. A first-in-class target with a dual mechanism stands out to pharma buyers.
- Cross-border structures can work. A Canadian company with Spanish science and US trials shows the reach of a well-built biotech.
- Strategic investors shape outcomes. Celgene’s involvement gave the programme industrial backing.
- Plan for several exits. Pipelines can be sold in parts to different buyers.
What oncology founders should prepare before the clinic
- A clinical development plan with budget and milestones.
- Manufacturing agreements and supply plans.
- IP and licence documentation.
- Accounts reconciled to the statutory filings in each country.
- A financing plan through the first data readout.
Finance for a clinical-stage oncology company
Oncology trials are expensive and recruit slowly. Each site has its own contract and budget, and costs accrue as patients are treated. A company running trials in several countries needs consistent reporting across entities and currencies. Investors expect to see spend against plan by programme, with clear forecasts of cash needs to each data point.
Metrix Partners in life sciences
Metrix has worked with Mosaic Biomedicals since its early stage. Other life sciences clients include AELIX Therapeutics and Ona Therapeutics.






